Low serum 1,25(OH)(2)D(3) in end-stage renal disease: is reduced 1α-hydroxylase the only problem?

Low serum 1,25-dihydroxyvitamin D (1,25(OH)(2)D) in end-stage renal disease (ESRD) is considered a consequence of elevated fibroblast growth factor 23 (FGF23) and concomitant reduced activity of renal 1α-hydroxylase (CYP27B1). Current ESRD treatment strategies to increase serum calcium and suppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Huish, Sharon A, Jenkinson, Carl, Dunn, Janet A, Meredith, David J, Bland, Rosemary, Hewison, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558908/
https://www.ncbi.nlm.nih.gov/pubmed/34519274
http://dx.doi.org/10.1530/EC-21-0372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558908/
https://www.ncbi.nlm.nih.gov/pubmed/34519274
http://dx.doi.org/10.1530/EC-21-0372

Ejemplares similares